Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial-Reference-Cited by-同舟云学术

Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial

Published:2022-05 Issue:10340 Volume:399 Page:2031-2046
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Ferrante Marc,Panaccione Remo,Baert Filip,Bossuyt Peter,Colombel Jean-Frederic,Danese Silvio,Dubinsky Marla,Feagan Brian G,Hisamatsu Tadakazu,Lim Allen,Lindsay James O,Loftus Edward V,Panés Julián,Peyrin-Biroulet Laurent,Ran Zhihua,Rubin David T,Sandborn William J,Schreiber Stefan,Neimark Ezequiel,Song Alexandra,Kligys Kristina,Pang Yinuo,Pivorunas Valerie,Berg Sofie,Duan W Rachel,Huang Bidan,Kalabic Jasmina,Liao Xiaomei,Robinson Anne,Wallace Kori,D'Haens Geert

Publisher

Elsevier BV

Subject

General Medicine

Reference23 articles.

1. IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease;Geremia;J Exp Med,2011

2. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene;Duerr;Science,2006

3. IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn's disease;Kobayashi;Gut,2008

4. Interleukin-23: immunological roles and clinical implications;Tan;Int J Biochem Cell Biol,2009

5. Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn's disease;Schmitt;Gut,2019

Cited by 97 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial;The Lancet Gastroenterology & Hepatology;2024-02

2. Biologics, small molecule therapies and surgery in small bowel Crohn's disease;Current Opinion in Gastroenterology;2024-02-01

3. Therapeutic Drug Monitoring for Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease;Medicina;2024-01-31

4. Real-world Effectiveness and Safety of Risankizumab in Patients with Moderate to Severe Multirefractory Crohn’s Disease: A Belgian Multicentric Cohort Study;Inflammatory Bowel Diseases;2024-01-12

5. Novel and emerging drugs for the treatment of Crohn’s disease: a review of phase II and III trials;Expert Opinion on Emerging Drugs;2024-01-09